No Data
No Data
Frontier Biotech (688221.SH): gradually launching pilot clinics for the prevention of exposure to Ecnotin in Shanghai and other areas.
On July 8th, Gelunhui reported that Front Bio(688221.SH) stated on the investor interaction platform that currently there are 0.1-0.15 million new HIV infections in China each year, more than 90% of which are transmitted through sexual activity. MSM (men who have sex with men) and high-risk heterosexual groups are both high-risk groups that urgently need to raise awareness of prevention. Timely PEP measures can help reduce HIV transmission. In the future, as the awareness of prevention and medication knowledge for high-risk groups improves after exposure, the market for HIV post-exposure prophylaxis medication will gradually open up. Ekkoning, as a long-acting anti-HIV injection, is a new drug in the field of AIDS prevention.
Frontier Biotechnologies Inc.'s (SHSE:688221) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 18% Last Week
Key Insights Frontier Biotechnologies' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by
About 160 million restricted shares of Frontier Biotech (688221.SH) will be listed for trading starting on July 1st.
The Frontier Biotech (688221.SH) announced that the restricted shares to be listed this time are part of the restricted shares publicly issued for the first time by the company, involving 8 shareholders of restricted shares, with a corresponding stock quantity of approximately 160 million shares, accounting for 42.7% of the total share capital of the company. This restricted shares will be listed and traded starting from July 1, 2024.
Frontier Biotech (688221.SH): will continue to explore and develop the advantages of using Echothiophate in the field of preventive treatment after exposure.
On June 21st, Gelunhui reported that Frontier Biotechnologies (688221.SH) stated on its investor interaction platform that Eclomin, as a long-acting injectable anti-HIV drug, has effective blocking, good compliance, and high safety in the field of AIDS prevention. 1) Targeting HIV envelope protein gp41, which acts on the first stage of HIV virus infection, can effectively block HIV virus; 2) As a long-acting drug, compliance is higher; 3) Peptide drugs are hydrolyzed into amino acids and water in the body, without liver metabolism, and have good safety. At the same time, according to two IIT studies initiated in 2023 and 2021.
Frontier Biotech (688221.SH): Epitinib has certain clinical irreplaceability.
On June 20th, Gelon Hui reported that Frontier Biotech (688221.SH) stated on the investor interaction platform that EKoning is effective for the main prevalent HIV-1 virus and drug-resistant viruses when used in combination with other anti-retroviral drugs. It has the characteristics of low medication frequency, fast onset, high resistance barrier, high safety, and small side effects. It has certain clinical irreplaceability for HIV hospitalized and critically ill patients, patients with abnormal liver and kidney function, drug-resistant patients, and immunocompromised patients, and long-term medication brings significant benefits to patients. Currently, AIDS is still incurable, and patients need lifelong medication, and specific medication plans need to be based on individual patient conditions.
Frontier Biotech (688221.SH): Passed pharmaceutical GMP compliance inspection.
On June 3rd, Gelunhui reported that Frontier Biotech (688221.SH) has recently received the "Drug GMP Compliance Inspection Results Notification" (No. 176 for 2024) issued by the Jiangsu Provincial Drug Administration. The freeze-dried powder injection production line located in the company's Nanjing Jiangning District production base has been inspected on-site by the Jiangsu Provincial Drug Administration and meets the requirements of the "Drug Production Quality Management Standard." The freeze-dried powder injection production line of the Zhidao Road production base has passed the Drug GMP Compliance Inspection, indicating that this production line meets the requirements of the "Drug Production Quality Management Standard." The new production line is in operation.
No Data